(Q33412763)

English

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Georg Hopfinger

object named as

Georg Hopfinger

1

0 references

object named as

Alexander Egle

7

0 references

8

object named as

Richard Greil

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Thomas Nösslinger

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alois Lang

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Werner Linkesch

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas Melchardt

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lukas Weiss

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

18 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

93

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

459-462

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2009-0

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2009-0

21 January 2018

Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2009-0

21 January 2018

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2009-0

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2009-0

21 January 2018

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2009-0

21 January 2018

Identifiers

10.1007/S00277-014-2009-0

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33412763&oldid=1980688289"